Hepatitis C virus treatment : highly effective therapy with direct acting antivirals and associated viral resistance / Kazuaki Chayama, editor.
Contributor(s): Chayama, Kazuaki,, editor literario
Material type:
E-bookPublisher: Singapore : Springer International Publishing, 2016Copyright date: 2017Description: 1 recurso en línea.ISBN: 9789811024160; 9811024162.Subject: Hepatitis C
Online resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC848.H425 H473 2016 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.20022413 |
Preface; Contents; 1: Treatment of€Chronic Hepatitis C with€the€First-Generation Protease Inhibitor Telaprevir: Its Efficacy and€Resistance Mutations; 1.1 Introduction; 1.2 Protease Inhibitors; 1.3 Telaprevir; 1.3.1 Clinical Trial Results; 1.3.2 Triple Therapy in€Clinical Practice; 1.3.3 Triple Therapy for€Genotype 2 Patients; 1.3.4 Telaprevir Treatment and€Resistance Mutations; 1.3.5 The Current Role of€Triple Therapy with€TVR; 1.4 Conclusion; References; 2: Features of€the€Second Wave of€the€First Generation Protease Inhibitors: Effect and€Tolerance; 2.1 Introduction.
2.2 Simeprevir2.3 Asunaprevir; 2.4 Vaniprevir; 2.5 Paritaprevir; 2.6 Conclusion; References; 3: The Efficacy of€Daclatasvir Plus Asunaprevir Combination Therapy with€Chronic Hepatitis; 3.1 Introduction; 3.2 DAA Mechanisms of€Action; 3.2.1 Protease Inhibitors: Asunaprevir; 3.2.2 NS5A Inhibitors: Daclatasvir; 3.3 Phase 3 Results of€Daclatasvir Plus€Asunaprevir Therapy in€Japan; 3.3.1 Treatment Results in€Patients Who Did Not Respond to€IFN-Based Therapy and€Patients Who Are IFN-ƯIneligible/Intolerant; 3.3.2 Treatment Results in€Treatment-Naïve Patients and€Prior Interferon Relapsers.
3.4 Appearance of€Resistance-Associated Variants in€Patients with€Virologic Failure3.5 Treatment Results After Approval of€the€Therapy; 3.6 Indications and€Cautions; 3.7 Conclusion; References; 4: Resistance-Associated Variants in€the€NS5A Region of€HCV and€Methods for€the€Detection; 4.1 Characteristics of€HCV-NS5A and€the€Action Sites of€NS5A Inhibitors; 4.2 Assay Systems to€Detect and€Quantify NS5A-RAVs of€Genotype-1b HCV; 4.3 Significance of€Amino Acid Mutations in€the€NS5A Region in€Patients with€HCV Infection; 4.4 Therapeutic Efficacies of€DAAs and€NS5A Polymorphisms; References.
5: Detection of€Antiviral Drug-Resistant Variants in€Chronic Hepatitis C by Deep Sequencing5.1 Introduction; 5.2 Deep Sequencing Analysis of€RAVs and€the€Aim of€RAV Analysis; 5.3 Interferon-Based DAA Therapy; 5.3.1 TVR/PEG-IFN/RBV Combination Therapy; 5.3.2 SMV/PEG-IFN/RBV Combination Therapy; 5.4 Interferon-Free DAA Therapy; 5.5 Conclusions; References; 6: Incidence and€Characteristics of€Naturally Occurring Drug-Resistant Hepatitis C Virus Strains; 6.1 Introduction; 6.2 Naturally Occurring Protease Inhibitor-Resistant Variants.
6.3 Naturally Occurring NS5A Inhibitor-Resistant Variants6.4 Naturally Occurring NS5B Inhibitor-Resistant Variants; 6.5 Conclusion; References; 7: Treatment Effects and Resistance-Associated Variants of Sofosbuvir Regimen for Japanese Patients with Chronic Hepatitis C Virus Genotypes 1 and 2; 7.1 The Mechanism of€Action of€Sofosbuvir and€a€Note of€Caution; 7.2 Characteristics of€Sofosbuvir; 7.3 Sofosbuvir/Ribavirin Therapy for€Genotype 2; 7.3.1 Study Design and€Patients Characteristics; 7.3.2 Efficacy and€Safety; 7.3.3 NS5B RAVs and€Sofosbuvir/Ribavirin Therapy.
There are no comments on this title.